Cefuroxime AxetilThird Party Manufacturing in India

Cefuroxime Axetil is a prodrug that is rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to release its active form, cefuroxime. Cefuroxime is a second-generation cephalosporin that exerts its bactericidal activity by interfering with bacterial cell wall synthesis. It binds to specific penicillin-binding proteins located in the bacterial cytoplasmic membrane, inhibiting the transpeptidase enzymes responsible for cross-linking the peptidoglycan network. This cross-linking is essential for maintaining the structural strength and shape of the bacterial cell wall. When inhibited, the cell wall becomes progressively weaker, ultimately leading to osmotic rupture and cell death.

Cefuroxime is notable for its increased stability against beta-lactamase enzymes compared to first-generation cephalosporins. This gives it an extended spectrum of activity against Gram-negative bacteria including Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, and Klebsiella species, while maintaining good activity against Gram-positive organisms such as Streptococcus pneumoniae and methicillin-sensitive Staphylococcus aureus. The prodrug formulation enables oral administration, with enhanced absorption when taken with food. The drug distributes well into respiratory tissues, tonsils, sinus mucosa, and middle ear fluid, making it effective for a wide range of community-acquired infections.

Therapeutic Uses

Cefuroxime Axetil is indicated for a wide range of infections:

• Upper Respiratory Tract Infections: Pharyngitis, tonsillitis, sinusitis, and acute otitis media caused by susceptible bacteria.
• Lower Respiratory Tract Infections: Community-acquired pneumonia, acute bronchitis, and acute exacerbations of chronic bronchitis.
• Uncomplicated Urinary Tract Infections: Effective against cystitis and other UTIs caused by Escherichia coli and Klebsiella pneumoniae.
• Skin and Soft Tissue Infections: Furunculosis, impetigo, cellulitis, and infected wounds caused by susceptible strains.
• Uncomplicated Gonorrhea: Oral alternative for the treatment of gonococcal infections.
• Early Lyme Disease: Effective for the treatment of erythema migrans in early Lyme disease.

Why Manufacturers Choose Cefuroxime Axetil

Cefuroxime Axetil is one of the most commonly prescribed oral antibiotics in India and globally. Its established safety profile, broad-spectrum coverage, and twice-daily dosing make it a first-line choice for many respiratory and ENT infections. The molecule is listed in multiple national treatment guidelines, ensuring consistent demand. Indian manufacturers produce it in 125mg, 250mg, and 500mg tablet strengths, catering to both adult and pediatric populations. Cefuroxime Axetil commands a significant share of the oral cephalosporin market, making it a profitable addition to any PCD franchise or contract manufacturing portfolio with steady export demand across regulated and emerging markets.